Inmune Bio, Inc.
No SEC Form 4 filings for $INMB in the last 30 days.
INmune Bio (INMB) reported Q2 2026 results on an earnings call, with net loss attributable to common shareholders of $1.3 million versus a prior-year $16.5 million impairment charge. Cash and cash equivalents were $18.4 million as of June 30, 2026, expected to fund operations into Q2 2027. The company discussed Ebstracel MHRA alignment and planned late-2026 conditional authorization, plus XPro Alzheimer MRI biomarker effects.
INmune Bio (NASDAQ: INMB) said a Department of Defense-funded peer-reviewed preclinical study in 3xTg-AD mice found traumatic brain injury increased soluble TNF, TNFR1, and Aβ42 and caused learning, memory, and pain deficits. Treatment with XPro1595 prevented the injury-driven rise in amyloid pathology and improved early cognitive and pain outcomes.
INmune Bio (INMB) said Phase 2 imaging data for XPro1595 in early Alzheimer’s will be presented at AAIC 2026 in London. Advanced MRI showed statistically significant Week 24 treatment differences in white matter myelin integrity (p<0.01) in the modified intent-to-treat group, with larger effects in biomarker-enriched patients. The company is advancing toward a Phase 2b/3 program.
Over the past 7 days, alphai's AI scored 1 news story mentioning INMB (Inmune Bio, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent INMB coverage spans technology, corporate actions and regulation.
The call combines cash runway updates with concrete regulatory-path milestones and new clinical readouts, which can re-rate probability-weighted timelines for Ebstracel and XPro.
Preclinical efficacy data strengthens the mechanistic case for XPro1595 in injury-accelerated Alzheimer’s biology, but it is not yet a clinical outcome catalyst.
Positive Phase 2 imaging readouts increase perceived biological activity for XPro1595, supporting the Phase 2b/3 adaptive plan.
AAIC presentation adds incremental clinical-efficacy support for XPro1595’s target engagement via concordant white and gray matter imaging endpoints.
U.S. national-phase entry plus a favorable PCT written opinion de-risks prosecution and supports long-dated IP value for its lead cell-therapy platform.
alphai scores every news story that mentions INMB with an AI model for sentiment and relevance, and aggregates insider trades from Inmune Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
INmune Bio (INMB) reported Q2 2026 results on an earnings call, with net loss attributable to common shareholders of $1.3 million versus a prior-year $16.5 million impairment charge. Cash and cash equivalents were $18.4 million as of June 30, 2026, expected to fund operations into Q2 2027. The company discussed Ebstracel MHRA alignment and planned late-2026 conditional authorization, plus XPro Alzheimer MRI biomarker effects.
7 min readINmune Bio (NASDAQ: INMB) said a Department of Defense-funded peer-reviewed preclinical study in 3xTg-AD mice found traumatic brain injury increased soluble TNF, TNFR1, and Aβ42 and caused learning, memory, and pain deficits. Treatment with XPro1595 prevented the injury-driven rise in amyloid pathology and improved early cognitive and pain outcomes.
4 min readINmune Bio (INMB) said Phase 2 imaging data for XPro1595 in early Alzheimer’s will be presented at AAIC 2026 in London. Advanced MRI showed statistically significant Week 24 treatment differences in white matter myelin integrity (p<0.01) in the modified intent-to-treat group, with larger effects in biomarker-enriched patients. The company is advancing toward a Phase 2b/3 program.
4 min readINmune Bio (NASDAQ: INMB) said it will present positive Phase 2 imaging results for XPro1595 in early Alzheimer’s at AAIC. The company reported statistically significant Week 24 treatment differences in white matter myelin integrity and concordant cortical microstructure changes, supporting selective soluble TNF inhibition target engagement. Poster details include longitudinal and subgroup analyses.
2 min readINmune Bio (NASDAQ: INMB) said it filed its CORDStrom™ platform patent application into the U.S. national phase with the USPTO after a favorable PCT written opinion. The claims cover composition-of-matter and methods for Ebstrocel (pobistrocel) for epidermolysis bullosa and related engineered MSC modalities, with potential protection into at least 2045 if granted.
3 min readInmune Bio, Inc. (INMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ea029662401ex10-1.htm FORM OF INDUCEMENT LETTER Exhibit 10.1 INMUE BIO INC. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 June 29, 2026 To the Holder of April 2024 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase
3 min readINmune Bio Inc. (NASDAQ: INMB) said the UK MHRA approved the Pediatric Investigation Plan for Ebstrocel™ for recessive dystrophic epidermolysis bullosa (RDEB). The company said this is the first step toward a UK marketing authorization application, aligned with an MAA in 2026 and a US accelerated approval filing in early 2027.
3 min readINmune Bio said the UK MHRA accepted written minutes from a May 12 pre-MAA Scientific Advice meeting for CORDStrom™/Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB). The agency aligned on CMC, non-clinical and clinical evidence, and noted MissionEB Phase 2 showed clinically meaningful symptomatic benefit (pain, itch), supporting chronic/intermittent supportive therapy positioning. The company plans a 2026 UK conditional MAA, with EU and US filings later.
3 min readInmune Bio, Inc. (INMB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029512901ex10-1.htm THIRD AMENDED AND RESTATED INMUNE BIO INC. 2021 STOCK INCENTIVE PLAN Exhibit 10.1 THIRD AMENDED AND RESTATED INMUNE BIO INC. 2021 STOCK INCENTIVE PLAN 1 General 1.1 Purpose . The purposes of the Third Amended and Restated INmune Bio Inc. 2021 Stock
2 min readINmune Bio (NASDAQ: INMB) reported exploratory chi-separation MRI results from its MINDFuL Phase 2 Alzheimer’s trial of XPro1595 (XPro). According to the company, after 24 weeks the full mITT group (n=200) showed a significant myelin treatment effect (p=0.0028; d=0.46), strengthening in inflammation-enriched patients (n=100; p=0.0098; d=0.59). The company plans to present full data at AAIC 2026.
4 min read
